Chang In Moon

Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers.

Jaehnig EJ, Fernandez-Martinez A, Vashist TD, Holt MV, Williams L, Lei JT, Moon CI, Kim BJ, Dou Y, Zhao H, Korchina V, Gibbs RA, Muzny DM, Doddapaneni H, Perou CM, Carey LA, Robles AI, Hyslop T, Wen Y, McCart L, Krek A, Petralia F, Miles G, Kavuri SM, Gillette MA, Mani DR, Carr SA, Zhang B, Ellis MJ, Satpathy S, Anurag M.

Cell Rep Med., 6(6):102154, 2025.

ClinicalOmicsDB: exploring molecular associations of oncology drug responses in clinical trials.

Moon CI^#, Elizarraras JM^#, Lei JT, Jia B, Zhang B.

Nucleic Acids Res, 52(D1):D1201-D1209, 2024. (# first authors)